October 14, 2024 06:28 AM EDTUpdated 06:38 AM
R&D

Trans­gene shares dip as ther­a­peu­tic can­cer vac­cine dis­ap­points in Phase 2 tri­al

Ayisha Sharma

News Reporter

Trans­gene’s ther­a­peu­tic can­cer vac­cine can­di­date has failed a mid-stage test in cer­tain HPV-dri­ven can­cers, send­ing its shares down around 14% Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

Catal­ent sells New Jer­sey plant to Bel­gian CD­MO, plans mov­ing HQ else­where

FDA to re­con­sid­er re­moval of Lil­ly's GLP-1 drug from short­age list, a win for com­pound­ing phar­ma­cies

Ex­clu­sive: British start­up rais­es $16M to find genes that rewind the epi­ge­net­ic clock

Pfiz­er gets an FDA win in he­mo­phil­ia af­ter a rough week

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times